In this issue:
HypoG-01: 3- vs. 5-week radiotherapy in early breast cancer
DESTINY-Breast-05: T-DXd vs. T-DM1 in residual HER2+ early breast cancer
J-START: incidence of advanced breast cancer with ultrasound + mammography
European trends in breast cancer incidence/mortality 1978–2019
TRAIN-3: a shortened neoadjuvant chemotherapy regimen guided by MRI
RxPONDER: cognitive impairment with endocrine therapy vs. chemotherapy + endocrine therapy
Fulvestrant + abemaciclib vs. imlunestrant + abemaciclib in HR+/HER2– breast cancer
Real-world outcomes in HR+/HER2− breast cancer after progression with endocrine therapy + CDK4/6 inhibitors
Neoadjuvant endocrine therapy + CDK4/6 inhibition vs. chemotherapy in HR+ breast cancer
CARABELA: neoadjuvant chemotherapy vs. abemaciclib + letrozole in HR+/HER2− highly proliferative breast cancer
Please login below to download this issue (PDF)